Roche Relief As APHINITY Trial Boosts Outlook On Its Oncology Business

Roche released positive headlines from its APHINITY trial examining use of Herceptin and Perjeta together in the adjuvant treatment of breast cancer, offering promise that its aging oncology franchise can be protected.